Business Description
BridgeBio Pharma Inc
NAICS : 325412
SIC : 2834
ISIN : US10806X1028
Total Employee Number:
839Description
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.29 | |||||
Equity-to-Asset | -2.07 | |||||
Debt-to-Equity | -0.99 | |||||
Debt-to-EBITDA | -5.06 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -2.91 | |||||
Beneish M-Score | -1.49 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 70.7 | |||||
3-Year EBITDA Growth Rate | -2.1 | |||||
3-Year EPS without NRI Growth Rate | -7.4 | |||||
3-Year FCF Growth Rate | 6.3 | |||||
3-Year Book Growth Rate | -8.8 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 71.27 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 42.3 | |||||
9-Day RSI | 42.08 | |||||
14-Day RSI | 44.36 | |||||
3-1 Month Momentum % | 29.02 | |||||
6-1 Month Momentum % | 27.24 | |||||
12-1 Month Momentum % | 57.66 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.23 | |||||
Quick Ratio | 1.17 | |||||
Cash Ratio | 0.81 | |||||
Days Inventory | 286.03 | |||||
Days Sales Outstanding | 81.14 | |||||
Days Payable | 252.8 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.9 | |||||
Shareholder Yield % | -1.03 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 94.44 | |||||
Operating Margin % | -67.01 | |||||
Net Margin % | -97.03 | |||||
EBITDA Margin % | -69.1 | |||||
FCF Margin % | -61.34 | |||||
OCF Margin % | -60.87 | |||||
ROA % | -61.74 | |||||
ROIC % | -107.65 | |||||
3-Year ROIIC % | -27.49 | |||||
ROC (Joel Greenblatt) % | -1627.45 | |||||
ROCE % | -77.41 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 231.91 | |||||
PS Ratio | 20.85 | |||||
EV-to-EBIT | -33.63 | |||||
EV-to-Forward-EBIT | -105.21 | |||||
EV-to-EBITDA | -33.97 | |||||
EV-to-Forward-EBITDA | -118 | |||||
EV-to-Revenue | 23.47 | |||||
EV-to-Forward-Revenue | 9.95 | |||||
EV-to-FCF | -38.23 | |||||
Price-to-GF-Value | 0.51 | |||||
Earnings Yield (Greenblatt) % | -2.97 | |||||
FCF Yield % | -2.93 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BridgeBio Pharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 614.27 | ||
| EPS (TTM) (€) | -3.067 | ||
| Beta | 2.1365 | ||
| 3-Year Sharpe Ratio | 0.71 | ||
| 3-Year Sortino Ratio | 1.47 | ||
| Volatility % | 36.42 | ||
| 14-Day RSI | 44.36 | ||
| 14-Day ATR (€) | 1.625575 | ||
| 20-Day SMA (€) | 69.4235 | ||
| 12-1 Month Momentum % | 57.66 | ||
| 52-Week Range (€) | 41.54 - 77.81 | ||
| Shares Outstanding (Mil) | 195.49 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BridgeBio Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BridgeBio Pharma Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-24 16:30 | In 175 days | ||
| Annual report for 2026 | 2027-02-24 | In 174 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-24 | In 174 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-29 16:30 | In 57 days | ||
| Third quarter earnings results for 2026 | 2026-10-29 | In 56 days | ||
| Guidance call for 2026 | 2026-09-23 09:40 | In 21 days | ||
| Morgan Stanley 24th Annual Global Healthcare Conference | 2026-09-15 10:00 | In 13 days | ||
| Guidance call for 2026 | 2026-09-10 09:10 | In 8 days | ||
| 21st Annual Wells Fargo Healthcare Conference | 2026-09-09 01:30 | In 7 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-10 16:30 | 71.44 (-0.08%) |
Show
Entries
BridgeBio Pharma Inc Frequently Asked Questions
What is BridgeBio Pharma Inc(FRA:2CL)'s stock price today?
The current price of FRA:2CL is €66.63. The 52 week high of FRA:2CL is €77.81 and 52 week low is €41.54.
When is next earnings date of BridgeBio Pharma Inc(FRA:2CL)?
The next earnings date of BridgeBio Pharma Inc(FRA:2CL) is 2026-10-29 Est..
Does BridgeBio Pharma Inc(FRA:2CL) pay dividends? If so, how much?
BridgeBio Pharma Inc(FRA:2CL) does not pay dividend.
Press Release
Articles on BridgeBio Pharma Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers